Booster HIV vaccine study for those who got the first shots
Part of Immune system & allergy, Infections clinical trials.
This study tests two booster doses of an HIV vaccine to see if they are safe and boost the immune system. It is for healthy adults who already received three earlier doses of a related vaccine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a generally healthy adult.
- You must have already received three doses of the BG505 SOSIP.GT1.1 gp140 HIV vaccine.
- You must be willing to get HIV testing and follow risk reduction advice.
- If you are female and could become pregnant, you must use effective birth control starting 2 weeks before the first shot and for 4 months after the last shot.
- You must not have HIV, certain blood or immune disorders, or recent risky behaviors for HIV infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental HIV vaccine in healthy adults, including those living with HIV. The goal is to see if the vaccine is safe and prompts an immune response.
This trial tests a new two-part HIV vaccine regimen in healthy adults without HIV. The goal is to see if it is safe and produces an immune response that could help prevent HIV.
This trial tests a combination of an HIV vaccine and a new antibody treatment (GS-2872) to see if it can help control HIV without daily pills. It is for people with well-controlled HIV who are looking for ways to reduce their dependence on antiretroviral therapy.
This study tests an experimental HIV vaccine that uses tiny particles and mRNA technology in healthy adults. If you qualify, you'll help researchers see if it's safe and if it triggers an immune response.
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.